Table 1.
Comparison of the clinical characteristics of responders and nonresponders to IFX after 1 year of treatment of CD patients.
| Characteristics | CD patients | P value | |
|---|---|---|---|
| Responders | Nonresponders | ||
| Number | 89 | 14 | |
| Age, mean ± SD (years) | 35.4 ± 12.9 | 37.8 ± 10.3 | 0.368 |
| Male/female (%) | 50/39 (56.2/43.8) | 9/5 (64.3/35.7) | 0.773 |
| Smoking (%) | 17 (19.1) | 5 (35.7) | 0.172 |
| Concomitant use of immunomodulators (%) | 20 (22.5) | 8 (57.1) | 0.007 |
| Colonic location (%)∗ | |||
| Ilium | 16 (18.0) | 2 (14.3) | 1.000 |
| Colon | 17 (19.1) | 3 (21.4) | 1.000 |
| Ileocolon | 56 (62.9) | 9 (64.3) | 1.000 |
| Disease behavior (%)∗ | |||
| Nonstricturing/penetrating | 43 (48.3) | 5 (35.7) | 0.409 |
| Stricturing | 37 (41.6) | 3 (21.4) | 0.238 |
| Penetrating | 18 (20.2) | 8 (57.1) | 0.006 |
∗Classification according to Montreal Classification for CD.
IFX: infliximab; CD: Crohn's disease; SD: standard deviation.